Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Apr
15
Today In Oncology
Is Standard of Care Optimal for the Individual Patient?
LuPSMA-617 and Pembrolizumab in mCRPC
ASH-ISTH Create Guidelines for Pediatric VTE Prophylaxis
Asbestos-Free Talc Not Associated With Increased Risk for Respiratory Cancers
New Molecular-Based Model for Classification and Risk in Chronic Myelomonocytic Leukemia
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo